Skip to main content

Table 3 Relationship between Stroma-AReactive-Invasion-Front-Areas and PSMA-positive recurrences in PET/CT imaging

From: SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

  

SARIFA-positive

SARIFA-negative

 

n in total: 57

 

n

in %

n

in %

 

PSMA-positive Recurrence

 

34

59.6

23

40.4

p-value

Local

no

20

58.8

14

60.9

0.877

 

yes

14

41.2

9

39.1

Regional Lymph Nodes

no

22

64.7

19

82.6

0.140

 

yes

12

35.3

4

17.4

Distant Lymph Nodes

no

29

85.3

23

100.0

0.066

 

yes

5

14.7

0

0.0

Bone

no

22

64.7

20

87.0

0.061

 

yes

12

35.3

3

13.0

Pulmonary

no

32

94.1

22

95.7

0.799

 

yes

2

5.9

1

4.3

Soft Tissue

no

34

100.0

23

100.0

/

 

yes

0

0.0

0

0.0

  1. p-values that are statistically significant are highlighted in bold
  2. Distant lymph nodes were defined as all extra-pelvic lymph node manifestations
  3. PET/CT Positron emission tomography/Computed tomography, PSMA prostate-specific membrane antigen, SARIFA Stroma-AReactive-Invasion-Front-Areas